4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

Rhea-AI Summary

4D Molecular Therapeutics (FDMT) has announced its participation in multiple upcoming investor conferences and the Ophthalmology Innovation Summit XIV. The company will engage in fireside chats at the Jefferies London Healthcare Conference on November 19, 2024 (12:00 p.m. GMT) and the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024 (1:45 p.m. ET). Additionally, Dr. Carlos Quezada-Ruiz will present at the Ophthalmology Innovation Summit XIV Gene & Cell Therapy Showcase on November 22, 2024 (4:40 p.m. PT). Webcasts will be available for up to one year on the company's investor relations website.

News Market Reaction

+4.02%

1 alert

+4.02% News Effect

On the day this news was published, FDMT gained 4.02%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in November and December and will present at the Ophthalmology Innovation Summit XIV. Members of the management team will also be available for one-on-one meetings at the respective investor conferences.

Jefferies London Healthcare Conference 2024

Presentation Date:	Tuesday, November 19, 2024
Presentation Time:	12:00 p.m. GMT
Webcast Link:	Webcast

7th Annual Evercore ISI HealthCONx Conference

Presentation Date:	Tuesday, December 3, 2024
Presentation Time:	1:45 p.m. ET
Webcast Link:	Webcast

Archived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

Ophthalmology Innovation Summit XIV

Session Title:	Gene & Cell Therapy Showcase
Presenter:	Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology
Presentation Date:	Friday, November 22, 2024
Presentation Time:	4:40 p.m. PT

About 4DMT

4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Katherine Smith
Inizio Evoke Comms
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com

FAQ

When is 4DMT (FDMT) presenting at the Jefferies London Healthcare Conference 2024?

4DMT will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT.

What conferences will 4DMT (FDMT) attend in November and December 2024?

4DMT will attend the Jefferies London Healthcare Conference, the 7th Annual Evercore ISI HealthCONx Conference, and the Ophthalmology Innovation Summit XIV.

Who will represent 4DMT (FDMT) at the Ophthalmology Innovation Summit XIV?

Dr. Carlos Quezada-Ruiz, SVP and Therapeutic Area Head of Ophthalmology, will present at the Gene & Cell Therapy Showcase.

How long will the 4DMT (FDMT) conference webcasts be available?

The webcasts will be available for up to one year on 4DMT's investor relations website.